Clinical Trials

Salivary Gland Neoplasms

NCT06695845 2026-02-25

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

55 enrolled

Salivary Gland Neoplasms

NCT05075980 2026-02-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT03740256 2026-02-06

VISTA

Phase 1 Recruiting

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04969835 2026-02-04

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1 Recruiting

158 enrolled

BreastGenitourinaryGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Salivary Gland Neoplasms, Sarcoma

NCT05553782 2026-01-26

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Phase EARLY_PHASE1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Salivary Gland Neoplasms

NCT03942653 2025-12-31

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

20 enrolled

GastrointestinalHead & NeckOther solid neoplasmThoracic

Salivary Gland Neoplasms

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Phase 1/2 Recruiting

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

300 enrolled

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT04452162 2025-09-09

PSGT

Phase NA Recruiting

Salivary Gland Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting